« Previous
Next »
Seminars in Radiation Oncology
Volume 13, Issue 1
, Pages
42-52
, January 2003
Combining bioreductive drugs and radiation for the treatment of solid tumors
-
Correlation between the hypoxic toxicity of various nitroheterocycles toward Chinese hamster V79 cells and the 1-electron reduction potential of the compounds. The more electron-affinic compounds (ie,
Correlation between the hypoxic toxicity of various nitroheterocycles toward Chinese hamster V79 cells and the 1-electron reduction potential of the compounds. The more electron-affinic compounds (ie, less negative reduction potential) showing the greater toxicity. ̂, 2-nitroimidazoles; ●, 5-nitroimidazles; ▵, 5-nitrofurons.
-
Growth delay of the MT fibrosarcoma grown in WHT mice given graded doses of radiographs. X, radiation only; ̂, mice given 1 mg/g misonidazole 30 minutes before irradiation; ●, ▵, mice given 1 mg/g miGrowth delay of the MT fibrosarcoma grown in WHT mice given graded doses of radiographs. X, radiation only; ̂, mice given 1 mg/g misonidazole 30 minutes before irradiation; ●, ▵, mice given 1 mg/g misonidazole 5 minutes after irradiation. The group of mice illustrated by the open triangle were held at 37°C for 3.5 hours after treatment with Misonidazole. Upward arrows indicate cures in those groups.26.
-
Mechanism of the reductive elimination of aspirin from a 2-nitroimidazole prodrug.68.Mechanism of the reductive elimination of aspirin from a 2-nitroimidazole prodrug.68.
-
Mechanism of the reductive elimination of an alkylating mustard from an indolequinone prodrug.69.Mechanism of the reductive elimination of an alkylating mustard from an indolequinone prodrug.69.
-
Tumor-free survival data for HT1080 (EGFP-5 and R-9) xenografts treated with radiographs plus or minus 250 mg/kg RB6145.77.Tumor-free survival data for HT1080 (EGFP-5 and R-9) xenografts treated with radiographs plus or minus 250 mg/kg RB6145.77.
☆ Supported by the Medical Research Council Grant Number G9520193.
☆☆ Address reprint requests to Ian J. Stratford, PhD, School of Pharmacy and Pharmaceutical Sciences, University of Manchester Coupland III Building, Oxford Road, Manchester M13 9PL, UK.
PII: S1053-4296(03)50007-8
doi: 10.1053/srao.2003.50008
« Previous
Next »
Seminars in Radiation Oncology
Volume 13, Issue 1
, Pages
42-52
, January 2003
